Lv11
10 积分 2025-01-07 加入
A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial
1小时前
待确认
A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change
3小时前
已完结
The Two-Year Results of Using Radiofrequency Ablation as a Novel Treatment for Persistent or Relapsed Graves’ Disease: A Prospective Study
1天前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
8天前
已完结
皖公网安备34019202002308
